Echelon Wealth Partners ascribed 2017 top pick status to Immunovaccine (TSX:IMV; OTCQX:IMMVF) while maintaining a “speculative buy” rating and $2.75 price target. The stock closed at $1.24 on Oct. 11.Read More
Echelon Wealth Partners initiated coverage of Theralase Technologies (TSXV:TLT) with a “speculative buy” rating and one-year price target of 90 cents. The stock closed at 47 cents on Sept. 1.Read More
Echelon Wealth Partners initiated coverage of Profound Medical (OTCQX:PRFMF; TSXV:PRN) with a “buy” rating and one-year price target of $4. The stock closed at 78 cents on March 14.Read More
Echelon Wealth Partners raised its price target for Neovasc (NASDAQ:NVCN) to $3.25 from $1.25 after the company sold its PeriPatch processing operations to Boston Scientific (NYSE:BSX). The stock closed at 86 cents on Dec. 2.Read More
Echelon Wealth Partners raised its price target for RepliCel Life Sciences (TSX-V:RP) to $2.15 from $1.50 after the company closed a unit offering that will add about $4.1-million in net cash to its balance sheet. The stock closed at $1.03 on Monday.
“The recapitalization provides funds to drive [RepliCel’s hair follicle-derived] non-bulbar dermal sheath cell platform forward with renewed vigor,” writes analyst Doug Loe, noting that he expects interim six-month data from a Phase 1/2 Achilles tendinosis/RCT-01 study by yearend.Read More